Improvement of IFNg ELISPOT Performance Following Overnight Resting of Frozen PBMC Samples Confirmed Through Rigorous Statistical Analysis by Santos, Radleigh et al.
Nova Southeastern University
NSUWorks
Mathematics Faculty Articles Department of Mathematics
12-24-2014
Improvement of IFNg ELISPOT Performance
Following Overnight Resting of Frozen PBMC
Samples Confirmed Through Rigorous Statistical
Analysis
Radleigh Santos
Torrey Pines Institute for Molecular Studies, radleigh@nova.edu
Alcinette Bunying
Torrey Pines Institute for Molecular Studies (TPIMS)
Nazila Sabri
Torrey Pines Institute for Molecular Studies (TPIMS)
John Yu
Cedars-Sinai; ImmunoCellular Therapeutics Ltd
Anthony Gringeri
ImmunoCellular Therapeutics Ltd
See next page for additional authors
Follow this and additional works at: https://nsuworks.nova.edu/math_facarticles
Part of the Mathematics Commons, and the Medicine and Health Sciences Commons
This Article has supplementary content. View the full record on NSUWorks here:
https://nsuworks.nova.edu/math_facarticles/234
This Article is brought to you for free and open access by the Department of Mathematics at NSUWorks. It has been accepted for inclusion in
Mathematics Faculty Articles by an authorized administrator of NSUWorks. For more information, please contact nsuworks@nova.edu.
NSUWorks Citation
Santos, Radleigh; Bunying, Alcinette; Sabri, Nazila; Yu, John; Gringeri, Anthony; Bender, James; Janetzki, Sylvia; Pinilla, Clemencia;
and Judkowski, Valeria A., "Improvement of IFNg ELISPOT Performance Following Overnight Resting of Frozen PBMC Samples
Confirmed Through Rigorous Statistical Analysis" (2014). Mathematics Faculty Articles. 234.
https://nsuworks.nova.edu/math_facarticles/234
Authors
Radleigh Santos, Alcinette Bunying, Nazila Sabri, John Yu, Anthony Gringeri, James Bender, Sylvia Janetzki,
Clemencia Pinilla, and Valeria A. Judkowski
This article is available at NSUWorks: https://nsuworks.nova.edu/math_facarticles/234
Cells 2015, 4, 1-18; doi: 10.3390/cells4010001 
 
cells 
ISSN 2073-4409 
www.mdpi.com/journal/cells 
Article 
Improvement of IFN ELISPOT Performance Following 
Overnight Resting of Frozen PBMC Samples Confirmed 
Through Rigorous Statistical Analysis 
Radleigh Santos 1, Alcinette Buying 2, Nazila Sabri 2, John Yu 3,4, Anthony Gringeri 4,  
James Bender 4,†, Sylvia Janetzki 5, Clemencia Pinilla 2,* and Valeria A. Judkowski 2,* 
1 Torrey Pines Institute for Molecular Studies, 11350 SW Village Parkway Port St. Lucie, FL 34987, 
USA; E-Mail: rsantos@tpims.org  
2 Torrey Pines Institute for Molecular Studies, 3550 General Atomics Court, San Diego, CA 92121, 
USA; E-Mails: abunying@tpims.org (A.B); nsabri@tpims.org (N.S) 
3 Cedars-Sinai, 8700 Beverly Blvd., Los Angeles, CA 90048, USA; E-Mail: John.Yu@cshs.org  
4 ImmunoCellular Therapeutics Ltd., 23622 Calabasas Road, Calabasas, CA 91302, USA;  
E-Mails: anthony.gringeri@imuc.com (A.G.); james.bender@lionbio.com (J.B.) 
5 ZellNet Consulting, 555 North Ave., Fort Lee, NJ 07024, USA; E-Mail: sylvia@zellnet.com  
† Present address: Lion biotechnologies, 21900 Burbank Blvd., Woodland Hills, CA 91367, USA. 
* Authors to whom correspondence should be addressed; E-Mails: pinilla@tpims.org (C.P.); 
vjudkowski@tpims.org (V.A.J.); Tel./Fax: +1-858-597-3883 (C.P.); +1-858-597-3869 (V.A.J.).  
Academic Editor: Alexander E. Kalyuzhny 
Received: 9 October 2014 / Accepted: 16 December 2014 / Published: 24 December 2014 
 
Abstract: Immune monitoring of functional responses is a fundamental parameter to 
establish correlates of protection in clinical trials evaluating vaccines and therapies to boost 
antigen-specific responses. The IFN ELISPOT assay is a well-standardized and validated 
method for the determination of functional IFN-producing T-cells in peripheral blood 
mononuclear cells (PBMC); however, its performance greatly depends on the quality and 
integrity of the cryopreserved PBMC. Here, we investigate the effect of overnight (ON) 
resting of the PBMC on the detection of CD8-restricted peptide-specific responses by IFN 
ELISPOT. The study used PBMC from healthy donors to evaluate the CD8 T-cell response 
to five pooled or individual HLA-A2 viral peptides. The results were analyzed using a 
modification of the existing distribution free resampling (DFR) recommended for the 
analysis of ELISPOT data to ensure the most rigorous possible standard of significance. The 
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results of the study demonstrate that ON resting of PBMC samples prior to IFN ELISPOT 
increases both the magnitude and the statistical significance of the responses. In addition, a 
comparison of the results with a 13-day preculture of PBMC with the peptides before testing 
demonstrates that ON resting is sufficient for the efficient evaluation of immune functioning. 
Keywords: overnight resting; PBMC; IFN ELISPOT; immune monitoring 
 
1. Introduction 
Immune monitoring is an essential component of immunological research, translational science and 
even clinical settings. Many different assays are available that allow the assessment of the immune 
system for a variety of phenotypes and functions [1]. These assays differ in their sensitivity, specificity, 
complexity, difficulty of validation and robustness. While some allow the assessment of the phenotypic 
or structural attributes of specific immune cells (e.g., MHC-peptide multimer staining), others measure 
their functional features (e.g., ELISPOT) and some both (e.g., intracellular cytokine staining). A key 
element for the functional evaluation of immune cells is the integrity of the sample. No test can 
compensate for flaws in the sample integrity. Many important sample preparation steps have been 
identified that aid in optimal sample preservation, including:  
1. The choice of anti-coagulant [2],  
2. The time frame between blood draw and PBMC isolation [3–5],  
3. The storage/shipping temperature of unprocessed blood [6],  
4. The effective removal of granulocytes/avoidance of granulocyte contamination [5,7],  
5. The optimal cryopreservation with pretested freezing medium that supports sample integrity [8],  
6. A careful thawing process [2,9] and  
7. The use of pretested media without suppressive or non-specific stimulation features [10].  
Two of the major factors for the suppression of functionality are the contamination of the sample with 
apoptotic cells, especially after cryopreservation [11,12], and the loss of a functional signaling platform 
in samples obtained from whole blood (e.g., PBMC) [13].  
Apoptotic cells can be found to varying degrees in most PBMC samples, with an average of about 
5% in thawed PBMC samples obtained from blood processed within eight hours of blood and frozen 
with pretested freezing media [14]. It has been shown that an increased number of apoptotic cells in a 
PBMC sample dramatically decreases the functionality of CD4 and CD8 cells as assessed by  
ELISPOT [11]. Based on a series of experiments in which Smith et al. correlated the degree of apoptosis 
in a sample with its ELISPOT responses against viral epitopes under the same standard operating 
procedure (SOP), a quality acceptance criterion for PBMC samples evaluated under that SOP was 
established using their degree of contamination with apoptotic cells (<18%). Further, Lenders showed 
in a series of experiments that apoptotic cells do not only contaminate the sample and decrease the 
amount of viable and, hence, potential responder cells, but that they also interfere with  
antigen processing [12].  
In early international proficiency panel studies, laboratories that assessed the amount of apoptotic 
cells in a thawed sample reported lower viability counts (on average, 4%–6% lower) compared to labs 
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that reported viability based on trypan blue assays (which count apoptotic cells as living cells), but 
performed better overall, with a higher response detection rate [14]. In addition, these studies also 
revealed that laboratories that implemented an overnight (ON) resting step had a favorable response 
detection and better panel performance [14,15]. This held true for repeated panel rounds, and ON resting 
was included as one of the recommendations of the initial ELISPOT harmonization guidelines, which 
have been shown to positively affect the ELISPOT performance and decrease the variability in results 
reported by different labs evaluating the same samples [16,17]. Recently, Kutscher et al. demonstrated 
that ON resting of cryopreserved PBMC leads to lower apoptotic cell and higher dead cell counts in the 
post-rest sample, illustrating that the resting procedure aids in the removal of apoptotic cells [18].  
In the presented study, we investigate the effect of ON resting of PBMC with impaired integrity due 
to delayed processing and long-term cryopreservation on their recall function to CD8-restricted peptides 
as measured by IFN ELISPOT. Using a modification of the existing distribution free resampling method 
(DFR) recommended for the statistical analysis of ELISPOT data [19], we apply p-value correction 
across all samples and stimuli, ensuring that the significances presented herein are subject to the most 
rigorous possible standard and that the resulting analyses have enhanced integrity. The study used five 
HLA-A2 peptides from the CEF (Cytomegalie, Epstein Barr, and Influenza virus) pool of 32 peptides, 
and it is denoted as A2-CEF. This pool provided reliable results when comparing the response to the five 
individual peptides, supporting its use for the immune monitoring of HLA-A2 samples. Lastly, the study 
includes a comparison of the results obtained from ON resting of cells with results obtained after a  
13-day-long in vitro stimulation (IVS) prior to testing. The results demonstrate that ON resting is 
sufficient for rescuing a recall response and its strength, as determined by statistical testing.  
2. Experimental Section  
This section was written in compliance with the Minimal Information about T-cell Assays (MIATA) 
guidelines [20]. These studies were conducted with established laboratory research protocols following 
exploratory research principles. Raw data are shown in Supplementary Tables 1S and 2S. The MIANKA 
(Minimal Information about NK cell Assays) and MIATA sub-modules are shown in Supplementary 
Table 3S. 
2.1. Human PBMC Samples 
Elutriated apheresis products from four HLA-A*0201 healthy donors (denoted H3, H4, H10 and 
H12), using citrate phosphate dextrose solution as an anti-coagulant, were obtained from Hemacare 
Corporation (Van Nuys, California). Apheresis products were received at a temperature of 15 to 20 °C 
and diluted with phosphate-buffered saline (PBS, Hyclone, Logan, UT) at a 1:1 ratio, aliquoted into  
50-mL tubes, spun down (1500 rpm, for 5 min) and suspended into RPMI1640 medium supplemented 
with 10% fetal bovine serum (FBS; Hyclone, Utah) for counting. The FBS lot was chosen based on 
optimal cell culture performance. The number of recovered PBMC upon processing ranged from  
12–16 × 109 cells per apheresis bag with an average viability of 94%. PBMCs were suspended in  
serum-free freezing medium (Cryostore10, Biolife Solutions, Bothel, WA) at a density of  
1 × 108 cells/mL in 2.0-mL cryovials at 1 mL per vial. Vials were frozen using a Mr. Frosty cryo-freezing 
container (Nalgene, Thermo Fisher Scientific, Waltham, MA) at −80 °C and transferred to liquid 
nitrogen within 24 h. The median time from finishing elutriation at Hemacare to the end of cell 
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processing at the Torrey Pines Institute for Molecular Studies (TPIMS) was about 36 h. Apheresis 
products from donors H3 and H4 were processed at Cedars-Sinai Medical Center, as described above, 
and shipped ON in vapor nitrogen containers to TPIMS, where the experiments where performed.  
2.2. Pretest Handling of PBMC 
PBMC were thawed in a 37 °C water bath, transferred to 50 U/mL of Benzonase-containing 
(Millipore, Darmstadt, Germany) culture medium made up of X-Vivo 15 medium (Lonza, Basel, 
Switzerland), 2 mM L-glutamine), 1% penicillin/streptomycin (all from Hyclone, Waltham, MA) and 
10% human AB serum (HS) (GemCell, West Sacramento, CA; pretested for optimal allogeneic 
expansion of human T-cell clones), washed and resuspended in culture medium without Benzonase. An 
aliquot of the cells was taken and counted with an automated cell viability counter based on trypan blue 
inclusion (Cellometer Auto 1000, Nexcelom, Lawrence, MA) prior to the evaluation with IFNγ 
ELISPOT. Viability in all experiments was confirmed to be from 50%–77% and the cell number 
recovered between 1.6 and 8.4 × 107 per vial. 
For PBMC with a resting period, the final concentration of the cells was adjusted to 2 × 106 cells/mL, 
and 5 mL were added to 50-mL conical tubes containing no more than 10 × 106 cells. The PBMC were 
rested ON for 18 or 22 h at 37 °C in a 5% CO2-humidified incubator with tube caps slightly loosened 
for gas exchange. The next day, the rested PBMC were washed twice, counted and resuspended in culture 
medium before seeding on an ELISPOT plate. The median viability of all of the samples after thawing 
was 65%, and the median recovery of “live” cells after ON resting for all samples was 67%, ranging 
between 34% to 100%. The viability and recovery did not vary significantly among the different resting 
times tested. PBMC that underwent an in vitro stimulation (IVS) were handled similarly to the ex vivo 
PBMC without the ON resting. The cells were thawed, treated with Benzonase, washed and counted. 
The IVS with antigenic peptides was done in a 24-well plate with a total volume of 2 mL per well. Each 
well contained 4 × 106 PBMC with a final concentration of 1 μg/mL of each peptide and 20 IU/mL of 
rhIL-2 (R&D Systems, Minneapolis, MN). The plates were incubated at 37 °C in a 5% CO2-humidified 
incubator, and half of the media was changed and replenished with culture medium containing rhIL-2 
on Days 4, 6, 8 and 11. On Day 13, the cells were harvested, washed twice, counted and resuspended for 
assessment by IFNγ ELISPOT. The median viability for all sample cultures upon IVS stimulation was 68%.  
2.3. ELISPOT Assay  
 
Figure 1. Summary of the experimental conditions used in the study. IVS, in vitro 
stimulation; PHA, phytohemagglutinin; CEF, Cytomegalie, Epstein Barr, and Influenza virus.  
a Only the peptides shown on bold were tested in the 13-day IVS. 
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2.4. Data Acquisition 
Wells were scanned and counted with the KS ELISPOT Imaging System (Carl Zeiss, Inc., 
Thornwood, NY) using KS ELISPOT software Version 4.9. The operator had previously participated in 
the Cancer Immunotherapy Consortium’s ELISPOT Plate Reading Panel, and the established consensus 
guidelines for plate evaluation were used to evaluate the ELISPOT plates. Specifically, a working set of 
counting parameters was established by comparing the appearance of negative control wells (cells alone) 
and antigen-stimulated wells (A2-CEF). The following parameters were fine-tuned to allow the inclusion 
of typical spots and the exclusion of artifacts: spot size, spot color and color saturation, intensity of 
staining (contrast), spot shape and degree of fading of color from spot center to its periphery. For each 
sample and experiment, the applicability of the working set of parameters was tested, and adjustments 
were made when the conditions required it (e.g., spot crowdedness required the adjustment of the spot 
separation algorithm; occurrence of many artifacts required the adjustment of spot-defining parameters 
for that sample, in order to efficiently exclude artifacts from being counted). Counts were always 
checked for plausibility, and all readings were audited. Representative datasets are provided (Figure 4).  
2.5. Statistical Analysis 
The use of Westfall–Young max-T correction on the difference between the log of the test sample 
count and the log of the control sample count (referred to as DFR(eq)) or on the difference between the 
log of the test sample count and twice the log of the background control count (referred to as DFR(2x)), 
has previously been shown to be the most powerful approach to analyzing single-experiment ELISPOT 
data while maintaining meaningful significances [19]. However, the goals of this study necessitated 
direct comparison of multiple experiments, in which multiple-comparison-related reduction of 
significance remained a problem using the existing DFR framework. We have therefore modified the 
DFR analysis procedure to carry out the multiple comparisons and to ensure that the significances 
presented in the study are meaningful.  
The ELISPOT spot results were analyzed for statistical significance at a given time point by 
comparing the number of spots for each of the tested peptides (triplicates) with the background controls 
(no peptide added, six replicates) at that time point. All ex vivo data from all experiments (Figures 2B 
and 3B, Table 1 and Supplementary Tables 1 and 2) had p-values simultaneously generated using the 
non-parametric one-tail Westfall–Young max-T correction as in DFR. Instead of the log-differences 
used in DFR, however, the test statistics: 
and: 
were used, where ்ܺതതതത is the average count of the test sample replicates, ܺ஼തതതത is the average count of the 
control sample replicates and: 
ܶ ൌ ்ܺതതതത െ ܺ஼തതതതߪ௣௢௢௟௘ௗ  (1) 
ܶ ൌ ்ܺതതതത െ 2ܺ஼തതതതߪ௣௢௢௟௘ௗ  (2) 
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is the pooled standard deviation, where ்ܰ and ஼ܰ are the sample sizes for the test and control samples 
(here, three and six) and ߪ் and ߪ஼ are the test and control sample standard deviations (SD), respectively. 
To avoid errors associated with artificially small variances, the minimum value allowed for ߪ௣௢௢௟௘ௗ was 
√ଷ଴
ଵ଴ , the maximum standard deviation of an n = 6 binary set. This choice of test statistic, because it is 
naturally normalized to the order of magnitude of the count, allows for comparison across different levels 
of activity without strongly active samples skewing the p-values, as they would with the log difference. 
We refer to this method as the modified DFR(eq) when: 
was used and the modified DFR(2x) when: 
was used. We refer to a result as strongly significant if the DFR(2x) p-value of that result is less than 
0.05 and moderately significant if it is not strongly significant, but the DFR(eq) p-value is less than 0.05. 
All p-values for IVS results (Table 1) were also generated simultaneously in the same manner and with 
the same nomenclature for significance and the same sample sizes.  
The statistical significance of the magnitude of responses between time points for each peptide was 
determined by comparing the normalized triplicate values for each peptide. The normalization at each 
time was done by subtracting the average of the six background replicates of the background controls to 
each of the triplicates of the peptide responses. p-values for comparisons between time points  
(Figures 2B and 3B) were then generated simultaneously using Westfall–Young max-T correction as in 
DFR, but again with a modified test statistic: 
written here to include the aforementioned normalization. Here, 
with: 
Strongly significant refers to a result with a p-value less than 0.05 and moderately significant to a  
p-value less than 0.10.  
  
ߪ௣௢௢௟௘ௗ ൌ ඨሺ்ܰ െ 1ሻߪ்
ଶ ൅ ሺ ஼ܰ െ 1ሻߪ஼ଶ
்ܰ ൅ ஼ܰ െ 2  (3)
ܶ ൌ ்ܺതതതത െ ܺ஼തതതതߪ௣௢௢௟௘ௗ  (4) 
ܶ ൌ ்ܺതതതത െ 2ܺ஼തതതതߪ௣௢௢௟௘ௗ  (5) 
ܶ ൌ ሺ௑೅భതതതതതതି௑಴భതതതതതതሻିሺ௑೅మതതതതതതି௑಴మതതതതതതሻఙ೛೚೚೗೐೏ ,  (6) 
ߪ௣௢௢௟௘ௗ ൌ ටሺே೅భିଵሻఙ೅భ
మାሺே೅మିଵሻఙ೅మమ
ே೅భାே೅మିଶ ,  (7)
்ܰଵ ൌ ்ܰଷ ൌ 3 (8) 
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3. Results and Discussion 
3.1. Overnight Resting of PBMC Samples Increases the Magnitude of the Response to the  
A2-CEF Pool  
To evaluate the impact of ON resting of PBMC samples on the responses measured by IFN ELISPOT 
testing, PBMCs from four different HLA-A*0201 individuals were tested for their reactivity to a pool 
of five HLA-A2.1-restricted viral peptides from influenza (Inf) virus, EBV and HCMV  
(A2-CEF; an A2-condensed version of the CEF pool, known as a reliable control for detecting CD8 
memory T-cell responses in PBMCs) [21]). Different vials of PBMC samples were non-rested (0 h. 
resting) or rested for 18 h or 22 h before testing. Responses from all donor PBMC samples to the  
A2-CEF pool at all three time points (0, 18 and 22 h) were positive and strongly statistically significant 
when compared with background control wells (PBMC alone) (see Figure 2A, Figure 2B, left, and the 
representative images of the ELISPOT results in Figure 4A). Although qualitative detection, as a matter 
of statistical significance, would not change based on whether the cells were rested (the  
p-values for all of the subjects at the three time points are <5%, shown in green on the left of Figure 2B), 
it is evident that the magnitude of the responses drastically increased after resting (Figure 2A and 
Supplementary Table 1). In particular, the magnitude of the response to the A2-CEF pool was 
statistically different between 0 h and 22 h. for all PBMC donor samples and statistically different 
between 0 h and 18 h for 3 PBMC donor samples (H12 being the exception), with the spot counts as 
measured at 22 h being higher (Figure 2A, right of Figure 2B and Supplementary Table 1). Furthermore, 
for three out of the four donors, PBMC responses were even significantly different between 18 h and 22 h 
(H4 being the exception).  
3.2. Overnight Resting of PBMC Samples Increases the Magnitude and Statistical Significance of 
Responses to Individual Peptides of the A2-CEF Pool  
To more effectively measure the effect of ON resting, each of the A2-CEF peptides included in the 
A2-CEF pool was tested individually (Figure 3 and representative images for EBV-1 in Figure 4B). 
TRP-2, a tumor associated antigen, was also included as a control. As summarized in Figure 3B, after 
ON resting, donors had not only more strong statistically significant responses to peptides, but also 
developed new moderate significant responses (left). Further, the magnitude of response upon resting 
increased significantly in multiple cases. The raw spot counts for each of the triplicate wells used for the 
evaluation of the peptides and for each of the six replicates used for background control are shown in 
Supplementary Table 1. 
Looking at specific examples, the response to EBV-2 by H10 is statistically significant only when 
cells are rested, and the statistical significances for EBV-2 and EBV-1 by H12 changes from moderate 
(yellow) to strong (green) when cells are rested for at least 18 h. The responses to Inf A, EBV-2 and 
EBV-1 by H4 are significant only after resting 22 h, albeit only moderately so (Figure 3B, left). Further, 
the magnitude of the response was found to be strongly statistically significant between no resting and 
either 18 h or 22 h of resting for Inf A and EBV-1 by H3, Inf M and EBV-2 by H4 and EBV-1 by H10 
(Figure 3B, right). Out of the total of 20 responses to the individual viral peptides evaluated in the four 
donors (4 donors × 5 single viral peptides), four responses (20%) were significantly different at 18 h 
compared to no resting and eight (40%) were significantly different at 22 h compared with no-resting. 
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Furthermore, the magnitude of the response was only statistically different between 18 and 22 h for 
EBV-1 by donor H10. This analysis suggests that 22 h of resting could be even more advantageous than 
18 h, but an 18-h resting period appears to be a sufficient resting timeframe for evaluating the T-cell 
responses to individual peptides. Of interest is the fact that the impact of resting the samples has been 
less remarkable in donor H12, whose samples have been stored in liquid nitrogen for a shorter time than 
the other three donors tested. Future studies including more samples and more variable storage periods 
could be considered. 
 
 
Figure 2. The magnitude of the response to the A2-CEF peptide pool in PBMC samples 
from normal donors increases with overnight resting. PBMC samples from the indicated 
donors were thawed and seeded in the presence and absence (no Ag, background control) of 
the A2-CEF peptide pool after 0 h, 18 h. or 22 h. of resting. (A) Results are the average of 
spots from triplicates wells. (B) Statistical significance for the responses to A2-CEF as 
compare to No Ag at each resting time were determined by modified DFR(2x) (DFR, 
distribution free resampling) after Westfall–Young max-T correction; p-values <5% are 
shown in green. The statistical significance of the responses obtained for the three different 
resting time points was determined by a DFR-like permutation method with Westfall–Young 
max-T correction; 5% or 10% significances are shown in dark blue or light blue, respectively. 
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Figure 3. Resting of PBMC samples prior to the evaluation of individual peptides of the  
A2-CEF pool increases the magnitude of response detected by IFNγ ELISPOT. PBMC 
samples from the indicated donors where thawed and seeded in the presence or absence (no 
Ag, background control) of peptide. The peptides included TRP-2 and each of the individual 
peptides from the A2-CEF pool. PBMCs were not rested (0 h) or rested 18 h or 22 h prior to 
testing. (A) Results are the average of spots from triplicate wells for wells tested with peptide 
and from six replicates in the absence of peptide. (B) The statistical significance for the 
response at each of the rest times was determined by modified DFR(2x) or DFR(eq) after 
Westfall–Young max-T correction, and p-values <5% are shown in green or yellow, 
respectively. The statistical significance of the responses obtained for the three different 
resting time points were determined by a DFR-like permutation method with Westfall-Young 
max-T correction; 5% or 10% significances are denoted by dark blue or light blue, respectively. 
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Figure 4. Representative images of the IFN ELISPOT performed with previously frozen 
PBMC. PBMC samples from donors H3, H4, H10 and H12 were thawed and stimulated  
(A) with the A2-CEF pool or (B) with EBV-1. PBMCs were not rested (0 h) or rested for  
18 h or 22 h prior to testing. Each picture is a representative of triplicate wells. Responses 
that were significantly different from 0 h were determined by a DFR-like permutation 
method with Westfall–Young max-T correction; 5% or 10% significances are denoted by 
(**) or (*), respectively. 
As can be observed in Figure 3B, many responses remained undetectable, even when resting the cells, 
such as the response to HCMV by H4. Indeed, out of the 14 responses that were negative without resting 
among all four donors, nine remained negative and five became positive after 18 or 22 h. of resting 
(Figure 3B). The only response that was detected without resting and not detected with resting was to 
HCMV and Inf M by donor H3; however, they were only moderately statistically significant, and this 
lack of detection after resting was not reproducible in an earlier experiment. In that experiment, moderate 
(Inf M) or strong (HCMV) significance resulted after resting 22 h., as well; see Supplementary Table 2. 
Lastly, no responses to TRP-2 were detected by any of the subjects, at any time point. This finding was 
not surprising, since TRP-2 is a tumor-associated antigen and the PBMCs used in this study were 
obtained from healthy donors. These results emphasize the specificity of resting effects on antigen-
specific responses and demonstrate that resting does not cause a non-specific increase of spot counts or 
induce false positives.  
3.3. The Quality of the Responses Is Not Improved by In Vitro Stimulation  
To assess whether IVS of PBMC with the viral peptides would improve the response detection, 
PBMCs of all four donors were stimulated for 13 days with two viral peptides and the tumor antigen 
TRP-2 and tested in ELISPOT. The results are shown in Table 1. Significances were calculated as 
described in the Experimental Section, but for a clearer demonstration of the magnitude of effect the 
data presented in the table, there is as an average fold increase (FI) over the background. FI values higher 
than 50 are derived either from peptide-stimulated wells that had counts 50-times higher than the 
background or too many spots to count (higher than 2000). As can be observed, all strongly significant 
IVS results were also at least moderately significant in ex vivo testing after resting. Although H12 
stimulated with HCMV changes from not significant to moderately significant after IVS, the background 
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reactivity observed in the IVS without any peptide (negative control) puts the overall response detection 
to peptides into question. Indeed, a similar observation was made for the response by H10 to the negative 
control TRP-2 peptide, which is moderately statistically significant for the IVS performed without 
peptide, but negative for the IVS with TRP-2 peptide. Overall, these data suggest that IVS does not 
provide clear advantages for detecting memory responses to viral peptide.  
Table 1. The comparison of IFN ELISPOT performance using ex vivo vs. IVS-PBMC 
samples shows that IVS stimulation prior to testing does not provide clear advantages for the 
determination of peptide immunogenicity. PBMC samples from the indicated donors were 
either thawed and rested for 22 h. (ex vivo) or thawed and stimulated with a pool of  
TRP-2, HCMV and influenza M peptides during 13 days (IVS-peptide stimulated) or thawed 
and left unstimulated for 13 days ( IVS-no peptide) prior to testing with each of the indicated 
individual peptides. The table shows the fold increase calculated as follows: AVG (average) 
of spots from triplicate wells tested with peptide/AVG of spots from six replicate background 
wells (no peptide). The statistical significance for the differences between the number of 
spots in the presence of peptide and background was determined by modified DFR(2x) or 
DFR(eq) after Westfall–Young max-T correction; p-value <5% responses are shown in 
green or yellow formatting, respectively.  
 Ex Vivo IVS-Peptide Stimulated IVS-No Peptide 
Donor/Peptide H3 H4 H10 H12 H3 H4 H10 H12 H3 H4 H10 H12 
TRP-2 1.9 0.5 0.6 0.5 0.6 0.7 1.2 1.3 1.6 1.5 1.3 1.1 
HCMV 5.3 1.0 0.9 0.2 >50 0.7 1.0 1.7 2.7 0.7 1.1 1.3 
Inf M 4.4 >50 11 19 11 >50 >50 >50 1.7 33 1.4 1.2 
3.4. Discussion 
In this study, a condensed version of the CEF peptide pool, containing only five A2-restricted peptides 
(A2-CEF), was used. Clearly, the strong significance level of A2-CEF responses observed in these study 
indicate that the A2-CEF peptide pool can be an effective control for CD8+ memory responses in HLA-A2 
subjects and may be of interest in light of cost-preserving measures. In immune monitoring efforts that 
include large panels of clinical samples with the need for confirmatory assay repeats, this can represent 
a significant cost savings. 
Equally apparent in the data is the advantage of resting the cells. Figure 2A and Table S1 clearly show 
that the number of spots in wells tested with peptide is higher in most cases after resting. In addition to 
the response to EBV-2 by H10 being undetected without resting, but detected with strong significance 
after resting 18 h, and the responses to Inf A, EBV-2 and EBV-1 by H4 being moderately detected only 
after 22 h resting, there was also an improvement in the significance of the detected stimulation from 
moderate to strongly significant in the responses to EBV-2 and EBV-1 by H12. Indeed, of the nine 
strongly significant results for individual peptides after resting 18 h, only two thirds were strongly 
significant without resting. The advantages to increasing the level of detected significance should not be 
underestimated, because, in general, moderately statistically significant results are less likely to 
reproduce than strongly significant results; as previously reported [19], DFR(eq) has a false positive rate 
of 10.7%, over five-times higher than that of DFR(2x) (2.0%). Direct comparisons between spot counts 
Cells 2015, 4 12 
 
 
associated with not resting versus resting also support this conclusion, with eight subject/stimulus 
combinations showing at least moderate significance between no resting and either (or both) 18 and 22 h 
of resting. Note that these significances do not always track with increases in significance overall. If the 
sample is already significant without resting, for example, then the significance between resting times 
will not be evident in the significance at each resting time. Conversely, because significances between 
resting times were the results of comparisons between two samples of a size of three, rather than three 
versus six background samples, as was the case of measuring the significance at each resting time, a 
change in significance after resting does not necessarily imply significance between those two 
measurements. 
Overall, moderately significant responses (yellow) were found in wells in which the number of spots 
was low (less than approximately 35). An excellent example of one way in which resting is advantageous 
to such a moderately significant sample is shown through analysis of the response of donor H12 to 
EBV2. The response to the peptide did not result in a particularly high spot count at 0 h., and the average 
spot count did not increase after resting; rather, there was a decrease in the number of background spots. 
Reduction in the number of spots for the background wells after resting for 18 and 22 h contributed to 
the increase of the statistical significance of the difference between background wells and peptide 
response (Supplementary Table 1), even though the unrested background number of spots was not 
unreasonably high. This shows that the background can be “cleaned up” by resting. Another observed 
example of such “cleaning up” was the removal of testing artifacts after resting (Figure 1S). Although 
this finding was observed in only one out of the four donors included in this study, it suggests that when 
analyzing a large number of donors, a nontrivial percentage of the samples may present artifacts in the 
background and, thus, will benefit from ON resting for the determination of peptide-specific T-cell responses.  
Both of these observations, the increase of spot counts and the decrease of artifacts, underline the 
applicability of the previously described benefits of ON resting. Small artifacts in ELISPOT are most 
commonly caused by dying cells during the assay incubation time. As Kutscher et al. convincingly 
showed, cells die during prolonged resting periods [18]; hence, less apoptotic cells are added to the actual 
assay, giving less cause for artifacts. Indeed, the percent recovery determined in the presented study also 
supports that observation. The median recovery of the seeded “live” cells for all samples after resting 
was 67%. Although, in this study, apoptotic markers were not used to confirm that these lost cells were 
undergoing apoptosis, our data shows that resting the cells is beneficial for reliable determination of 
peptide-specific T-cell responses. Future studies comparing the performance of freshly isolated PBMC 
with rested cryopreserved samples could be performed in order to determine which of the tested resting 
conditions more accurately resemble the freshly-isolated PBMC performance. In addition, the fact that 
cells were cryopreserved at a high concentration (100 × 106 cells/vial) could have contributed to the 
effect of overnight resting; however, the results presented here clearly show that samples that are 
potentially impaired due to processing steps can highly benefit from the effects of overnight resting prior 
to testing. ELISPOT results using rested PBMC samples derived from clinical studies that have been 
cryopreserved at a concentration of 5 to 20 × 106 cells/vial have shown, in general, low background 
responses and variance (manuscript in preparation) [22]. 
It should also be noted that the improvements associated with ON resting are not simply an alternative 
to using more cells, even if it is practical to do so (i.e., cell scarcity is not an issue). A doubling of all 
values in this study would lead to exactly the same significances, since the factor of two would cancel 
in the numerator and denominator of the test statistic. A doubling of the number of replicates would not 
Cells 2015, 4 13 
 
 
offer substantial benefit either, as it would only improve non-significant samples with high variance. 
Resulting from the multiple aforementioned biological processes that occur during ON resting, the 
improvement in detectability of responsive cells presented here as a result of ON resting is far more 
universal in its benefit, especially since non-responders continue to be non-significant rather than 
presenting as false positives. 
Furthermore, using polychromatic flow experiments, Kutscher et al. demonstrated that the quantity, 
as well as the quality of T-cells responding to viral antigens changes after resting. As the  
mono-functional T-cell fraction decreased upon ON resting, the fraction of multi-functional T-cells, as 
well as their antigen sensitivity increased. Importantly, tetramer assessment revealed that the actual 
number of TCR-specific T-cells does not change during the resting period. This fact is important for 
obtaining reliable estimates of true precursor frequencies of antigen-specific T-cells, even after  
ON resting.  
An enlightening insight into the mechanism related to the benefits (as the increase in responses, as 
observed in the study presented here) of resting cells before functionally assessing them is given by 
Roemer et al. [13]. Their work is based on the acknowledgement that the cells typically assessed in most 
studies consist of circulating cells (PBMC), which contain less than 1% of the body’s T-cells. It had 
already been shown in the murine model that T-cells entering the circulation lose their primed stage [23]. 
Roemer shows that the expression of phosphotyrosine, a key player of the signal complex assembly, is 
low in circulating T-cells, but is regained after high density culture, correlating with a recovery of CD4 
functionality. The cellular interactions during the high density resting period were necessary for 
functional maturation, which include the provision of weak TCR signals from HLA scanning [24], as 
well as the upregulation of the sensitivity to TCR signals [25]. Similar effects of resting periods were 
recently presented for CD8+ cells, postulating that high density preculture of PBMC resets cells to a 
tissue-like state with a proper functioning signaling platform [26].  
Interestingly, the data presented here show that in vitro culture of PBMCs for 13 days results in a 
similar qualitative detection of antigen-specific T-cells at 22 h. There was only one case in which IVS 
led to the detection of a significant response that resulted in being negative when tested ex vivo (H12 
with HCMV, Supplementary Table 2). 
The ELISPOT results associated with this study comprised a total of 164 separate comparisons 
between stimulated and background control wells, over all subjects and stimuli. Studies that analyze 
large datasets to determine a significant change in response, but that use arbitrary criteria, such as 
doubling of spot numbers [27] rather than p-values and statistical significances versus background, lack 
analytical rigor. In particular, these methods are incapable of giving p-values and correcting for multiple 
comparisons and, hence, cannot quantify the Type I error (i.e., the theoretical false positive rate) of the 
study. The importance of accounting for multiple comparisons in the determination of statistical 
significance has been previously highlighted [19,28]. Also highlighted in these publications were the 
difficulties associated with differing orders of magnitude of response; the standard DFR framework, 
which uses difference in the log of the average spot number as its test statistic, corrects within a given 
stimulus, but does not correct between stimuli, because the magnitude of two stimulus responses can 
disrupt the ability for a permutation method, like Westfall–Young correction, to properly account for 
sample randomness. Herein, we have attempted to overcome this issue via using an alternative test 
statistic, namely the standardized difference between the sample and control means. It should be 
emphasized that this statistic was the only change to the existing DFR framework of generating p-values 
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using Westfall–Young correction; although this statistic is used in the Student’s t-test, the Student’s  
t-test was found previously to be suboptimal for these analyses [19], likely because of the failure of the 
ELISPOT data to be normally distributed. When this statistic is used in the context of Westfall–Young 
correction, however, it was quite effective at generating adjusted p-values across stimuli; the 
standardized difference between the sample and control means is capable of making comparable data 
with different orders of magnitude by normalizing the count difference by the standard deviation, placing 
all data on the same scale (i.e., the number of standard deviations above the control). Thus, in this study, 
all p-values were simultaneously corrected across all experiments, making stronger any findings of 
significance in the process. In particular, DFR(2x) would have indicated 87 total significant results; 
modified DFR(2x) indicated only 72, with 10 becoming only moderately significant and five losing 
significance altogether; DFR(eq) indicated 14 significant results in addition to the above, and 11 of them 
lost significance in modified DFR(eq). p-value corrections of IVS results were more similar to DFR, 
with five DFR(eq) significant values becoming non-significant and no change in significance in those 
significant in the DFR(2x) analysis. In general, decreasing the false positive rate can potentially increase 
the false negative rate, but by making the significance results in this study extremely unlikely to be false 
positives associated with multiple comparisons, and the results are thus more accurately representative 
of a true reflection of the pre- and post-resting detection ability in general future contexts. 
Previous studies have demonstrated the benefits of ON resting [14,15,29]. Furthermore, two large 
HIV networks, the HVTN (HIV Vaccine Trials Network) and the IAVI (International Aids Vaccine 
Initiative), included the ON resting into their SOP [30,31]. However, it should be noted that a recent 
study [27] has presented an analysis of a seemingly similar experimental set-up without coming to this 
conclusion. In addition to having methodological differences, such as sample condition, freezing and 
ON resting methodologies, and differing cut-off criteria, Kuerten et al. approached the analysis and 
interpretation of the data in a manner that is not able to accurately reflect the benefits of ON resting. In 
particular, by applying a single statistical test to all samples in a given response category, the authors 
limit themselves to determining whether ON resting causes an overall increase in spot count for all 
samples. However, stating that the overall effect of ON resting is not significant because all samples do 
not increase in spot count essentially penalizes samples for not improving after resting. For this to be a 
valid means of analysis, all samples would have to be expected to yield a positive response; this 
assumption is not true in the case of the antigens used in the present study and is certainly false in the 
general research and immunomonitoring setting. Since, in general, there will be samples containing no 
cells with specific reactivity for some of the antigens tested (i.e., there will be truly negative responders), 
one needs to specifically focus on the ability of resting the cells to improve the detection of the samples 
that do contain cells specific for the antigen tested (i.e., are truly positive responders). Indeed, to avoid 
false positives, it is a benefit if ON resting does not make true negative responses significant. The fact 
that ON resting does not increase non-specific reactivity has also been previously reported [29]. It is 
important to note that this distinction in behavior between responders and non-responders can also be 
observed in the results as presented in Kuerten et al.; a greater overall increase in stronger responders 
(i.e., samples that are most likely to have responsive cells) was observed as compared to weak responders 
(i.e., samples that may be comprised of truly negative responding cells), implying that the results of these 
studies may agree and that the difference is a matter of analysis and interpretation of the data. Our 
analysis demonstrates the improvement in response detection in the most rigorous and non-assumptive 
statistical way possible, through the generation of distribution-free, multiple comparison-corrected  
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p-values, and not by simply grouping possibly disparate responder-types based on unrested response; 
this strict statistical analysis revealed the clear advantage of ON resting. 
Importantly, our observed results fit into recently published observations addressing the benefits and 
outcomes of extended resting of thawed PBMC on their functionality [13,18,32], as demonstrated with 
different experimental approaches. ELISPOT is one of the most commonly used tests in the immune 
monitoring setting. Most studies use frozen PBMC for batch testing. Freezing and thawing procedures 
can induce an increased rate of apoptosis, leading to a dilution of the test population with non-responsive 
cells, which may further impact the antigen processing. Further, there is only limited feasibility of 
obtaining cells from relevant tissue, e.g., tumor-infiltrating T-cells (TILs), exist [33]. If such samples are 
available, they can only be obtained in small samples sizes, and repeated availability (as for numerous 
time points) is close to impossible. The resting approach appears to offer a partial solution to the dilemma 
in that it can provide conditions that aid in resetting T-cells to a tissue-like state with an improved 
responsiveness to the antigens of interest. Such improved responsiveness in samples that are relatively 
easy to obtain (e.g., PBMCs) is essential for reliable immune monitoring in translational research and 
clinical trials, in order to guide the development of biomarkers and new immunotherapies [16]. 
In summary, the results presented here strongly support the implementation of an ON resting step of 
previously-frozen PBMC samples for the detection of peptide-specific responses by ELISPOT testing, 
a step that has already been identified as a critical protocol variable in ELISPOT and, hence, has been 
incorporated in ELISPOT harmonization guidelines [14,15,30]. One of the reasons for a slow adaptation 
rate of this recommendation has been the fear of losing too many cells. However, a possible lower 
recovery of cells after resting has to be accepted, since cells lost were likely undergoing apoptosis and, 
hence, would have not responded in the assay. As a matter of fact, the cells recovered contain less 
apoptotic cells, hence posing a lower risk for impaired antigen processing, and contain cells with a 
recovered signaling platform for efficient immune functioning. Although viral antigens were used in the 
presented study, these finding should be easily applicable to samples from clinical trial subjects, 
especially in light of the questionable sample functionality, due to the often apparent difficulties in 
obtaining PBMCs in a timely manner. The results presented clearly demonstrate the positive influence 
of extended resting on the quality of the antigen-specific response detection and its statistical significance.  
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